MINI REVIEW
published: 26 March 2021
doi: 10.3389/fonc.2021.641376

VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature

Aikaterini Liapi 1*, Patrice Mathevet 2, Fernanda G. Herrera 1, Delfyne Hastir 3 and Apostolos Sarivalasis 1

1 Département d’oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, 2 Département de Gynécologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, 3 Institut Universitaire de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

OPEN ACCESS

Edited by:
Alberto Farolfi,
Romagnolo Scientific Institute for the Study and Treatment of Tumors (IRCCS), Italy

Reviewed by:
Barbara Costantini,
Catholic University of the Sacred Heart, Italy
Chiara Fabbroni,
Istituto Nazionale dei Tumori (IRCCS), Italy

*Correspondence:
Aikaterini Liapi
aikaterini.liapi@chuv.ch

Specialty section:
This article was submitted to Women’s Cancer, a section of the journal Frontiers in Oncology

Received: 14 December 2020
Accepted: 19 February 2021
Published: 26 March 2021

Citation:
Liapi A, Mathevet P, Herrera FG, Hastir D and Sarivalasis A (2021) VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature. Front. Oncol. 11:641376. doi: 10.3389/fonc.2021.641376

INTRODUCTION

Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors, originating from the perivascular epithelioid cell-line (PEC) (1, 2). PEComas are characterized by co-expression of melanocytic and myoid markers including actin, desmin, HMB-45, and Melan-A (3). S100 and CK are rarely expressed (4). The World Health Organization (WHO) defines PEComas as “mesenchymal tumors composed of histologically and immunohistochemically distinctive
perivascular cells.” PEComas is a relatively new subgroup of tumors, first described in 1992. Under the initial description, PEComas only included angiomyolipoma (AML) and clear cell “sugar” tumor of the lung (CCST). Currently, lymphangioleiomyomatosis (LAM) has also been added to the PEComa family (4, 5). Although not all subsets of PEComas present malignant behavior, a considerable proportion exhibit malignant features including high proliferation rate and cytological atypia.

PEComas can occur at any age, but they are more common in the fourth decade. They affect more often women, which suggests a potential role of hormones in pathogenesis (6, 7). PEComas have tropism for the retroperitoneum, the kidneys and the genitourinary tract, but rarely can affect other localizations. As far as uterine PEComas are concerned, they are usually located in the corpus. Rarely the uterine cervix can also be involved (1, 5). The differential diagnosis of uterine PEComas is large and includes all types of uterine malignant and benign tumors. Especially challenging is their radiological distinction from smooth muscle tumors namely leiomyomas, a frequent benign tumor present in up to 80% of middle age women (8). PEComas can also be misdiagnosed for carcinomas, especially if visceral or cervical involvement is present, mimicking clear cell or other subtypes radiological characteristics.

The pathogenesis of PEComas is not yet fully understood. It has been hypothesized that these tumors are associated with tuberous sclerosis complex (TSC). This tumor-suppressor gene syndrome is caused by inactivation of TSC1 and TSC2, encoding hamartin and tuberin, respectively (9). These two proteins form a heterodimeric complex with inhibitor effect to the mammalian target of rapamycin (mTOR) activity. Inactivation of the tuberin/hamartin complex, results from a germline and/or loss-of-function mutation of either TSC1 or TSC2 genes. Subsequent permanent activation of mTOR promotes cell growth. Similar mutations have also been detected in sporadic, not associated with TSC, PEComas (10, 11).

Many different angiogenesis inhibitors were reported effective for advanced PEComa treatment (4). Angiogenesis is a complex web of cytokines and receptors with intracellular and nuclear cascades for signal transmission. They are intimately related to tumor genesis, proliferation and invasion. Vascular endothelial growth factor (VEGF) over-expression is a prognostic factor, associated with increased risk of metastases and decreased overall survival, in patients with solid tumors. The VEGF receptors (VEGFR) are a family of tyrosine kinase (TK) receptors that include VEGFR-1, VEGFR-2, and VEGFR-3 expressed among tumor microenvironment stromal cells and endothelial cells. The platelet derived growth factor (PDGF) and its receptor (PDGFR) family includes PDGFR, c-Kit, and Flt-3. Their main effect is the proliferation and migration of cells.

The treatment of PEComas can be challenging, as there are no prospective trials nor established standard treatment guidance. Despite mTOR inhibitors, resistant or progressive diseases treatment is unclear. In this challenging context, where commonly used chemotherapies including anthracyclines, taxanes, and anti-metabolites have marginal or no effect, prospective research is urgently needed to determine second line treatment options (12). In our report, we present the efficacy of the 2nd line treatment by pazopanib, a multi-tyrosine kinase inhibitor, in a patient with a metastatic uterine PEComa, progressing after 2 years of everolimus treatment.

**CASE REPORT**

A 53 year-old woman presented a 4-month history of vaginal bleeding without associated abdominal pain or other symptoms. On the gynecological examination, a right side, para-uterine mass was detected. The vaginal ultrasound and MRI showed the 6 × 6 cm mass with no associated lymph node involvement. The PET-CT identified a single bone lesion in the sacral spine (S1). Tumor markers including CEA, CA125, CA19-9, and CA15-3 were within normal range.

The patient underwent radical hysterectomy and bone biopsy. Both bone biopsy and hysterectomy indicated an oligo-metastatic uterine PEComa, without cervical involvement, with high-grade nuclear features and lymphovascular invasions (Figure 1). The tumor expressed CD10, the myoid smooth muscle actin and HMB45. Focal anti-TFE3 was also observed (11, 13). The single bone metastasis was treated with radiotherapy (5 fractions of 7 Gy for a total of 35 Gy).

Three months later, the patient presented asymptomatic bone, lung and subcutaneous recurrence. Targeted NGS (52-cancer gene hotspot panel) detected no mutation but a heterozygous deletion of 9q34 that contains the TSC1 gene (Figure 2) (14), prompting a first line everolimus treatment (10 mg 1×/day, po) (15). For the bone metastasis, denosumab (120 mg 1/month sc) was initiated, and a quarterly follow-up by PET-CT as well as regular clinical surveillance was decided. On this treatment, the disease was controlled for 2 years, but unfortunately the patient started feeling pain in the subcutaneous lesion of the right thigh and clinical progression was noted. The PET-CT showed bone, lung and
subcutaneous progression. A second line treatment by pazopanib and denosumab was introduced, based on reports on anti-angiogenic tyrosine kinase inhibitors (TKIs) effect in PEComas (16, 17) (Table 1).

During the treatment, the patient had regular clinical, biological and radiological controls. With the combination of pazopanib (800 mg 1×/day po) and denosumab, there was regression of the subcutaneous disease and stability of lung and bone metastasis for over a year (Figure 3). It is important to note that all the treatments were well-tolerated, only with mild toxicities. No dose adaptation was necessary.

**DISCUSSION**

Both sporadic and TSC associated PEComas present mTOR pathway alterations. This provided the rational for rather successful use of mTOR inhibitors including sirolimus, everolimus or temsirolimus. Despite being a rare tumor with no specific randomized controlled trial assessing the optimal treatment sequence, mTOR inhibitors are currently considered the most effective treatment option for metastatic PEComas (25–29). In the case of our patient, single agent everolimus treatment at the standard dose of 10 mg per day was effective for up to 2 years. Albeit this observation, it should be noted that in the reported cases the response rate and PFS varies, with a PFS of 9 months (4), according to the clinical context and previous prescribed treatments.

At the time of symptomatic progression, the therapeutic plan of our patient became even more challenging. Since no targetable alteration was detected in the 52-genes tumor DNA sequencing, we underwent a literature review on Scopus and PubMed. The key word used were “metastatic” and “PEComa,” “uterine perivascular epithelioid cell tumor,” “soft tissue sarcomas,” “mTOR,” “treatment.” We selected publications from 2000 to 2019.

The review pointed out potential benefit from anti-angiogenic treatment as an effective therapeutic option for our patient (16, 17). Furthermore, the local funding system enables pazopanib treatment for soft tissue sarcomas.

Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor, which has activity against VEGF-1–3, PDGFRα- β and KIT, resulting in tumor growth blockage and angiogenesis inhibition. The Phase III, placebo-controlled, double-blind PALETTE trial, comparing the efficacy of pazopanib vs. placebo in patients with non-adipocytic soft tissue sarcoma already treated with doxorubicin, showed a significant increase in PFS with pazopanib (4.6 vs. 1.6 months; \( P < 0.001\)); ORR was 6%. Median OS was 12.5 months with pazopanib vs. 10.7 months with placebo, but was not statistically significant (HR: 0.86, 95% CI: 0.67–1.11; \( p = 0.25\)). There is no precision on whether patients with PEComas were included in the trial (16). The SPIRE trial showed the activity of pazopanib in patients with soft tissue sarcomas, based on reports on specific histological subtypes (17). Two of the patients included in the trial were diagnosed with PEComas.

Sunitinib and regorafenib are approved for gastrointestinal stromal tumor (GIST), but not for other STS, as the clinical trials of these agents as STS treatment are limited to single-arm phase II trials (30, 31).


| Trail                                                                 | Anti-VEGFR | Phase | Total No. of patients | No. of patients with PEComa | No. of patients receiving anti-VEGFR | Line of treatment | Response |
|----------------------------------------------------------------------|------------|-------|-----------------------|-----------------------------|-------------------------------------|-------------------|----------|
| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial | Pazopanib  | III   | 372                   | Not specified              | 246                                 | Any               | 14 PR, 164 SD, 57 PD. Median PFS 4.6 mos, OS 12.5 mos |
| Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study | Pazopanib  | II    | 211                   | 2                          | 211                                 | Mostly second- and third-line | 0 CR, 15 PR, 38 SD. Median OS 11.1 mos, |
| Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas) | Pazopanib, sorafenib, sunitinib | Observational | 53 | 53 | 12: 9 pazopanib, 2 sorafenib, 1 sunitinib | 3 second-line, 4 third-line, and 5 fourth- or more lines. | 1 PR (sorafenib), 9 SD, 2 PD. Prolonged disease stabilization (12 mos): patients (pazopanib, sorafenib) |
| Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remarkable response of rapid progressive Uterine PEComa | Sorafenib  | Case-report | 1 | 1 | 1 | First | CR 7 months (then lost of follow up) |
| 1450P—systemic therapy in perivascular epithelioid cell tumors (PEComa) | Pazopanib, sunitinib | Observational | 49 | 49 | 4; pazopanib or sunitinib | 1–7 (no more info) | 1 PR and 2 SD, with a median PFS 7.3 mos, SD 9 months |
| Metastatic perivascular epithelioid cell tumor of the kidney: a case report with emphasis on response to the tyrosine-kinase inhibitor sunitinib | Sunitinib  | Case-report | 1 | 1 | 1 | First | SD 9 months |
| Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma | Pazopanib  | Observational | 115 | Not specified | 18 | Any | PFS 3 months, OS 14 months |
| Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety | Apatinib    | II    | 64                   | not specified              | 64                                 | After chemotherapy failure | 0 CR, 10 PR, 41 SD, 8 PD, median PFS 7.93 mos |
| Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California | Pazopanib  | Observational | 123 | 1 | 123 | Any (median number of prior lines: three) | 1 CR, 12 PR, 34 SD, 76 PD. Median PFS 3 months |

(Continued)
| Trail                                                                 | Anti-VEGFR | Phase       | Total No. of patients | No. of patients with PEComa | No. of patients receiving anti-VEGFR | Line of treatment                                      | Response |
|----------------------------------------------------------------------|------------|-------------|-----------------------|------------------------------|-------------------------------------|--------------------------------------------------------|----------|
| Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043) | Pazopanib  | PHASE II    | 142                   | Not specified                 | 142                                  | No more than 2 prior lines of cytotoxic treatment        | 0 CR 9 PR |
| The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study | Pazopanib  | Retrospective | 156                   | Not specified                 | 156                                  | Any                                                    | 13 PR, 74 SD, median PFS 15.4 weeks                   |
AUTHOR CONTRIBUTIONS

AL elaborated, drafted, reviewed the manuscript, and analyzed the patient’s data. PM and FH drafted and reviewed the manuscript. DH elaborated and analyzed the pathology. AS elaborated, drafted, reviewed the manuscript, and coordinated publication. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Conlon N, Soslow RA, Murrali R. Perivascular epithelioid tumours (PEComas) of the gynaecological tract. J Clin Pathol. (2015) 68:418–26. doi: 10.1136/jclinpath-2015-202945
2. Bonetti F, Pea M, Martinogni G, Zamboni G. PEC and sugar. Am J Surg Pathol. (1992) 16:307–8. doi: 10.1097/00000478-199203000-00013
3. Horrick JL, Fletcher CD. PEComa: what do we know so far? Histopathology. (2006) 48:75–82. doi: 10.1111/j.1365-2559.2005.02316.x
4. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. (2005) 29:1558–75. doi: 10.1097/01.pas.0000173232.22117.37
5. Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antonio G, et al. Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas). Clin Cancer Res. (2019) 25:5295–300. doi: 10.1158/1078-0432.CCR-19-0288
6. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. (2003) 188:100–7. doi: 10.1067/mob.2003.99
7. Sadigh S, Shah P, Weber K, Sebro R, Zhang P. Primary malignant perivascular epithelioid cell neoplasm (PEComa) of the bone mimicking granular cell tumor in core biopsy: a case report and literature review. Oncol Lett. (2018) 15:2946–52. doi: 10.3892/ol.2017.7662
8. Pan CC, Chung MY, NgKF, Liu CY, Wang JS, Chai CY, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomylipoma. J Pathol. (2008) 214:387–93. doi: 10.1002/path.2289
9. Musella A, De Felice F, Kyriacou Kyriacou A, Barletta F, Maria Di Matteo F, Marchetti C, et al. Perivascular epithelioid cell neoplasm (PEComa) of the uterus: a systematic review. Int J Surg. (2015) 19:1–5. doi: 10.1016/j.ijsu.2015.05.002
10. Bennett JA, Braga AC, Pinto A, Van de Vijver K, Cornejo K, Pesci A, et al. Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors. Am J Surg Pathol. (2018) 42:1370–83. doi: 10.1097/PAS.0000000000001119
11. Schoolmeester JK, Dao LN, Sukov WR, Wang L, Park KJ, Murrali R, et al. TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol. (2015) 39:394–404. doi: 10.1097/PAS.0000000000000349
12. Machado I, Cruz J, Lavernia J, Rayon JM, Poveda A, Llombart-Bosch A. Malignant PEComa with metastatic disease at diagnosis and resistance to several chemotherapy regimens and targeted therapy (m-TOR inhibitor). Int J Surg Pathol. (2017) 25:543–9. doi: 10.1177/1066896917701245
13. Nellist M, Brouwer RW, Kokke CE, van Veghel-Plandsoen M, Withagen-Schouten E, Winterberg A, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. (1999) 277:805–8. doi: 10.1126/science.277.5327.805
14. Starbuck KD, Drake RD, Budd GT, Rose PG. Treatment of advanced malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature. Anticancer Res. (2016) 36:6616–4. doi: 10.21873/anticancer.11208
15. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PEComa): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. (2012) 379:1879–86. doi: 10.1016/S0140-6736(12)60651-5
32. Maki RG, D’Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *J Clin Oncol.* (2009) 27:3133–40. doi: 10.1200/JCO.2008.20.4495

33. Gao F, Huang C, Zhang Y, Sun R, Zhang Y, Wang H, et al. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remarkable response of rapid progressive uterine PEComa. *Cancer Biol Ther.* (2016) 17:595–8. doi: 10.1080/15384047.2016.1167290

34. D’Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheuer K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. *J Clin Oncol.* (2005) 23:7135–42. doi: 10.1200/JCO.2005.16.139

35. Sanfilippo R, Fabbroni C, Fucà G, Fumagalli E, Morosi C, Sbaraglia M, et al. Addition of antiestrogen treatment in patients with malignant PEComa PROGRESSING to mTOR inhibitors. *Clin Cancer Res.* (2020) 26:5534–8. doi: 10.1158/1078-0432.CCR-20-1191

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liapi, Mathevet, Herrera, Hastir and Sarivalasis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.